Skip to main content
. 2017 Oct 30;1(24):2147–2160. doi: 10.1182/bloodadvances.2017006593

Figure 2.

Figure 2.

BRAFV600Eproduces more aggressive disease in the Eμ-TCL1 mouse model. B-cell–specific expression of BRAFV600E significantly shortens (A) leukemia onset and (B) overall survival (P < .001 comparing BRAFVE vs BRAFWT and BRAFCA for both onset and overall survival).